Core Viewpoint - The 11th batch of national organized drug centralized procurement has officially launched, emphasizing principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and countering price wars" [1] Group 1: Price Control Mechanism - The new procurement rules optimize the selection of price control "anchors," moving away from simply choosing the lowest bid to prevent abnormal low pricing from disrupting the market [2] - When the lowest price is below 50% of the average bid, the price control anchor will be set at 50% of the average bid, potentially increasing the average bid by 34% and up to 170% for certain products [2] - Companies are required to provide a rationale for any bids below the anchor price, detailing cost components such as manufacturing costs and sales profits [2] Group 2: Market Competition and Quality - The optimization of price control anchors is expected to reduce vicious low-price competition, allowing larger companies with strong brand influence to maintain market share and focus on quality and innovation [3] - Smaller companies attempting to capture market share through low pricing will face limitations, encouraging them to enhance product quality and competitiveness [3] Group 3: Revival Mechanism - The new "non-selected revival" rule allows companies that did not win bids to re-enter the selection process under certain conditions, increasing the number of selected companies and ensuring stable supply [4] - Conditions for revival include meeting average hospital demand, not being the highest bidder in the first round, and voluntarily lowering prices to match selected companies [4] Group 4: Anti-Collusion Measures - The introduction of a "first report leniency" mechanism aims to dismantle collusion among companies, promoting fairness in the procurement process [6][7] - Companies providing evidence of collusion will receive leniency in penalties, and strict measures will be enforced against colluding companies, including being placed on a "violation list" [6][7] - Continuous optimization of procurement rules is intended to ensure the sustainability and effectiveness of the centralized procurement system, ultimately benefiting public access to medications [7]